| 股票名称 | 机构名称 | 性质 | 变动前持股 | 变动后持股 | 持股比 | | --- | --- | --- | --- | --- | --- | | 美瑞健康国际 | Shunda Investment | 好仓 | 23.22 亿股 | 23.28 亿股 | 56.86%(最新) | | (02327) | Limited | | | | 56.71%(前次) | | 美瑞健康国际 | Zhongjia U-Home | 好仓 | 13.57 亿股 | 13.64 亿股 | 33.31%(最新) | | (02327) | Investment Limited | | | | 33.16%(前次) | | () | 袁亚康 | 好仓 | 4202.01 万股 | 4069.23 万股 | 12.82%(最新) | | | | | | | 13.24%(前次) | | () | 深圳市康成亨资本 | 好仓 | 4202.01 万股 | 4069.23 万股 | 12.82%(最新) | | | 管理集团有限公司 | | | | 13.24%(前次) | | () | HHLR Advisors ...

香港联交所最新资料显示，9月3日，美瑞健康国际(02327)股东将股票由中信证券香港转入民银证券， 转仓市值1.06亿港元，占比9.41%。 美瑞健康国际发布截至2025年6月30日止6个月中期业绩，该集团取得收益1745.3万港元，同比减少 41.89%；公司拥有人应占溢利1515.7万港元，同比增加79.05%；每股盈利0.37港仙。 ...

（原标题：美瑞健康国际(02327)股东将股票由中信证券经纪香港转入民银证券 转仓市值1.06亿港元） 智通财经APP获悉，香港联交所最新资料显示，9月3日，美瑞健康国际(02327)股东将股票由中信证券香 港转入民银证券，转仓市值1.06亿港元，占比9.41%。 美瑞健康国际发布截至2025年6月30日止6个月中期业绩，该集团取得收益1745.3万港元，同比减少 41.89%；公司拥有人应占溢利1515.7万港元，同比增加79.05%；每股盈利0.37港仙。 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 美瑞健康國際產業集團有限公司 呈交日期: 2025年9月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02327 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | HKD | | 0.01 HKD | | 100,000,000 | | 增加 / 減少 (-) | | | 0 | | | HKD | | | | 本月底結存 | | | 10,000,000,000 | HKD | | 0.01 HKD | | 100,000,000 | 本月底法定/註冊股本總額： HKD ...

Core Viewpoint - 美瑞健康国际 reported a significant decline in revenue for the six months ending June 30, 2025, with a total revenue of HKD 17.453 million, representing a year-on-year decrease of 41.9% [1] Financial Performance - Revenue for the period was HKD 17.453 million, down 41.9% year-on-year [1] - Gross profit amounted to HKD 14.161 million, reflecting a decrease of 8% compared to the previous year [1] - Profit attributable to owners of the company was HKD 15.157 million, which is an increase of 79.1% year-on-year [1] - Basic earnings per share were HKD 0.0037, with a proposed interim dividend of HKD 0.0015 per share [1]

Core Viewpoint - 美瑞健康国际 (02327) reported a decrease in revenue but an increase in profit attributable to shareholders for the six months ending June 30, 2025, indicating a mixed financial performance [1] Financial Performance - The company achieved revenue of 17.453 million HKD, a year-on-year decrease of 41.89% [1] - Profit attributable to shareholders was 15.157 million HKD, a year-on-year increase of 79.05% [1] - Earnings per share stood at 0.37 HKD [1] Profit Analysis - The after-tax profit for the six months ending June 30, 2025, was approximately 15.10 million HKD, compared to 8.20 million HKD for the same period in 2024, reflecting an increase of about 6.90 million HKD or approximately 84.1% [1] Revenue Drivers - The increase in profit was primarily due to: - Growth in property-related business revenue and profit, with rental income rising from approximately 8.20 million HKD to about 10.00 million HKD [1] - Interest income increased from approximately 8.90 million HKD to about 14.80 million HKD [1] - Positive financial impact from foreign exchange gains, which rose from approximately 4.40 million HKD to about 5.80 million HKD [1]

Core Viewpoint - Meizhou Health International (02327) reported a mixed performance for the six months ending June 30, 2025, with a significant decrease in revenue but a notable increase in profit attributable to shareholders [1] Financial Performance - The company achieved revenue of HKD 17.453 million, a year-on-year decrease of 41.89% [1] - Profit attributable to shareholders was HKD 15.157 million, reflecting a year-on-year increase of 79.05% [1] - Earnings per share stood at HKD 0.37 [1] Profit Analysis - The after-tax profit for the six months ending June 30, 2025, was approximately HKD 15.1 million, up about HKD 6.9 million or approximately 84.1% compared to HKD 8.2 million for the same period in 2024 [1] - The increase in profit was primarily due to: - Growth in property-related business revenue and profit, with rental income rising from approximately HKD 8.2 million to about HKD 10 million [1] - Interest income increased from approximately HKD 8.9 million to about HKD 14.8 million [1] - Positive financial impact from foreign exchange gains, which rose from approximately HKD 4.4 million to about HKD 5.8 million [1]

EF001 免責聲明 | 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 | | --- | --- | | 股票發行人現金股息公告 | | | 發行人名稱 | 美瑞健康國際產業集團有限公司 | | 股份代號 | 02327 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 | 截至2025年6月30日止六個月之中期股息 | | 公告日期 | 2025年8月28日 | | 公告狀態 | 新公告 | | 股息信息 | | | 股息類型 | 中期（半年期） | | 股息性質 | 普通股息 | | 財政年末 | 2025年12月31日 | | 宣派股息的報告期末 | 2025年6月30日 | | 宣派股息 | 每 股 0.0015 HKD | | 股東批准日期 | 不適用 | | 香港過戶登記處相關信息 | | | 派息金額及公司預設派發貨幣 | 每 股 0.0015 HKD | | 匯率 | 1 HKD ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任 何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 MEILLEURE HEALTH INTERNATIONAL INDUSTRY GROUP LIMITED 美 瑞 健 康 國 際 產 業 集 團 有 限 公 司 （ 於 百 慕 達 註 冊 成 立 之 有 限 公 司 ） （股份代號：2327） 截至二零二五年六月三十日止六個月 中期業績公告 業績 董事會欣然宣佈本集團截至二零二五年六月三十日止六個月之未經審核中期業績， 連同截至二零二四年六月三十日止六個月之比較數字如下： 1 中期簡明綜合損益表 4 截至二零二五年六月三十日止六個月 | | | 截至六月三十日止六個月 | | | --- | --- | --- | --- | | | | 二零二五年 | 二零二四年 | | | 附註 | 千港元 | 千港元 | | | | （未經審核） | （未經審核） | | 收益 | 4 | 17,453 | 30,033 | | 銷售貨品及提供服務的成本 | ...

Core Viewpoint - Meirui Health International (02327) expects a significant increase in shareholder profit for the six months ending June 30, 2025, projected between approximately HKD 14 million to HKD 16 million, compared to approximately HKD 8.2 million for the same period ending June 30, 2024 [1] Group 1: Profit Expectations - The anticipated increase in profit is primarily due to growth in property-related business revenue and profit, driven by increased rental income and stable fair value of investment properties for the six months ending June 30, 2025, in contrast to a significant decline in fair value for the same period in 2024 [1] - Interest income has risen as the company effectively utilized idle funds to provide short-term interest-bearing loans and long-term revolving financing to clients and related parties [1] Group 2: Challenges - The domestic operating environment remains challenging, leading to a decrease in trade sales and revenue from health and medical-related products [1]